<i>Retracted</i>: Role of CXCL12–CXCR4 axis in ovarian cancer metastasis and CXCL12–CXCR4 blockade with AMD3100 suppresses tumor cell migration and invasion in vitro

Liu, Yan; Ren, Chen; Li, Yang; Xu, Yiming; Chen, Yan‐Nan

doi:10.1002/jcp.27163

Cited by 35 publications

(26 citation statements)

References 38 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, in cohort 1, the total number of patients with a T3 and T4 stage tumor in the CXCR4‐H group was higher than that in the CXCR4‐L group. These results are consistent with previous studies reporting that in patients with high CXCR4 expression, both the depth of tumor invasion and the amount of distant metastasis are higher than those in patients with a low expression [33,34]. The difference between the cohorts may be explained by the absence of patients with a T1 stage tumor in cohort 1, which may limit the power of the statistical analysis.…”

Section: Discussionsupporting

confidence: 91%

Chemokine receptor 4 expression is correlated with the occurrence and prognosis of gastric cancer

Wang

et al. 2020

FEBS Open Bio

View full text Add to dashboard Cite

Gastric cancer (GC) is a common tumor with a low 5‐year survival rate. The chemokine receptor 4 (CXCR4) protein contributes to the progression and prognosis of GC, but the relationship between CXCR4 and immune infiltration, somatic copy number alteration (SCNA), tumor purity, tumor mutation burden (TMB), cytolytic activity (CYT), and drug sensitivity in GC is poorly understood. This study aimed to systematically explore the role of CXCR4 in GC. Microarray and RNA‐seq data were collected from the Gene Expression Omnibus and The Cancer Genome Atlas. Our analysis shows that CXCR4 is correlated with various types of immune cells. Patients with high CXCR4 expression had a higher fraction of B cells and CD8+ T cells, and a lower fraction of CD4+ T cells. In addition, high CXCR4 expression was associated with more advanced tumor stage, worse prognosis and higher stromal score, immune score, and cytolytic activity (P < 0.05). High CXCR4 expression also correlated with lower tumor purity and TMB. In summary, our analyses suggest that CXCR4 may affect the progression and prognosis of GC by influencing immune infiltration, TMB, CYT, tumor purity, and drug sensitivity.

show abstract

Section: Discussionsupporting

confidence: 91%

Chemokine receptor 4 expression is correlated with the occurrence and prognosis of gastric cancer

Wang

et al. 2020

FEBS Open Bio

View full text Add to dashboard Cite

show abstract

“…Accumulating studies have proved that SDF‐1 and its receptor, CXCR4, play a crucial role in tumor initiation, progression and migration, and their interaction mediates abundant downstream signaling pathways such as AKT serine kinase 1 mechanistic target of rapamycin kinase and extracellular regulated MAP kinase signaling pathways 34 . The SDF‐1/CXCR4 signaling pathway participates in metastatic process in many cancer types such as liver cancer, colorectal cancer and breast cancer 35 . CXCR4 is widely expressed in CD43 + cancer stem cells and SDF‐1 is widely expressed in tumor endothelial cells 36 .…”

Section: Discussionmentioning

confidence: 99%

“…34 The SDF-1/CXCR4 signaling pathway participates in metastatic process in many cancer types such as liver cancer, colorectal cancer and breast cancer. 35 CXCR4 is widely expressed in CD43 + cancer stem cells and SDF-1 is widely expressed in tumor endothelial cells. 36 Therefore, CXCR4 + tumor stem cells can migrate or invade along the SDF-1 concentration gradient to seed in distant tissues or organs.…”

Section: Parametersmentioning

confidence: 99%

Adenosine A2A receptor activation reduces brain metastasis via SDF‐1/CXCR4 axis and protecting blood‐brain barrier

Chen

Zhou

et al. 2020

Molecular Carcinogenesis

View full text Add to dashboard Cite

Brain metastasis is a leading cause of death worldwide, but the mechanism involved remains unclear. Stromal cell‐derived factor‐1 (SDF‐1)/C‐X‐C motif chemokine receptor 4 (CXCR4) signaling has been reported to induce the directed metastasis of cancers, and adenosine A2A receptor activation suppresses the SDF‐1/CXCR4 interaction. However, whether A2A receptor activation implicates the SDF‐1/CXCR4 signaling pathway and thus modulates brain metastasis remains unclear. In this study, Western blot was performed to evaluate the protein levels. Cell invasion and migration assays were used to estimate the metastasis ability of PC‐9 cells. The viability of cells was demonstrated by lactate dehydrogenase and cell proliferation assays. And the findings in vitro were further identified in nude mice. Notably, adenosine A2A receptor activation inhibited the proliferation and viability of PC‐9 cells and thus suppressed the brain metastasis. A2A receptor stimulation protected the function of blood‐brain barrier (BBB). The suppression of brain metastasis and the protection of BBB by A2A receptor relied on SDF‐1/CXCR4 signaling, and treatment using A2A receptor agonist and CXCR4 antagonist protected the nude mice from malignancy metastasis in vivo. Adenosine A2A receptor activation suppressed the brain metastasis by implicating the SDF‐1/CXCR4 axis and protecting the BBB.

show abstract

“…We demonstrated that CXCR4 dots were similar to untreated animals when we considered extracts from GMI-1271, whereas this seems to be reduced in tumors treated with GMI-1359 or CTCE-9908, suggesting that GMI-1359 and CTCE-9908 are actually inhibiting CXCR4 since was reported that CXCR4 antagonists reduce CXCR4 expression in vivo due to internalization and degradation [60]. In Figure 4G we added a graphical representation of densitometric units collected for the single immune-spot grouped for each therapeutic arm.…”

Section: Compared Effects Of Gmi-1359 Ctce-9908 and Gmi-1271 Single mentioning

confidence: 66%

Dual CXCR4 and E-Selectin Inhibitor, GMI-1359, Shows Anti-Bone Metastatic Effects and Synergizes with Docetaxel in Prostate Cancer Cell Intraosseous Growth

Festuccia

Mancini

Gravina

et al. 2019

Cells

View full text Add to dashboard Cite

Metastatic castration resistant prostate cancer (mCRPC) relapses due to acquired resistance to docetaxel-based chemotherapy and remains a major threat to patient survival. In this report, we tested the effectiveness of a dual CXCR4/E-selectin antagonist, GM-I1359, in vitro and in vivo, as a single agent or in combination with docetaxel (DTX). This agent was compared to the single CXCR4 antagonist, CTCE-9908, and E-selectin antagonist, GMI-1271. Here we demonstrate that CXCR4 antagonism reduced growth and enhanced DTX treatment in PCa cell lines as well as restored DTX effectiveness in DTX-resistant cell models. The efficacy of dual antagonist was higher respect to those observed for single CXCR4 antagonism. GM1359 impacted bone marrow colonization and growth in intraventricular and intratibial cell injection models. The anti-proliferative effects of GMI-1359 and DTX correlated with decreased size, osteolysis and serum levels of both mTRAP and type I collagen fragment (CTX) in intra-osseous tumours suggesting that the dual CXCR4/E-selectin antagonist was a docetaxel-sensitizing agent for bone metastatic growth. Single agent CXCR4 (CTCE-9908) and E-selectin (GMI-1271) antagonists resulted in lower sensitizing effects compared to GMI-1359. These data provide a biologic rationale for the use of a dual E-selectin/CXCR4 inhibitor as an adjuvant to taxane-based chemotherapy in men with mCRPC to prevent and reduce bone metastases.

show abstract

Retracted: Role of CXCL12–CXCR4 axis in ovarian cancer metastasis and CXCL12–CXCR4 blockade with AMD3100 suppresses tumor cell migration and invasion in vitro

Cited by 35 publications

References 38 publications

Chemokine receptor 4 expression is correlated with the occurrence and prognosis of gastric cancer

Chemokine receptor 4 expression is correlated with the occurrence and prognosis of gastric cancer

Adenosine A2A receptor activation reduces brain metastasis via SDF‐1/CXCR4 axis and protecting blood‐brain barrier

Dual CXCR4 and E-Selectin Inhibitor, GMI-1359, Shows Anti-Bone Metastatic Effects and Synergizes with Docetaxel in Prostate Cancer Cell Intraosseous Growth

Contact Info

Product

Resources

About